ASND
Price
$173.10
Change
+$1.10 (+0.64%)
Updated
Jul 2 closing price
Capitalization
10.47B
68 days until earnings call
CASI
Price
$1.33
Change
-$0.00 (-0.00%)
Updated
Jul 2 closing price
Capitalization
20.61M
Interact to see
Advertisement

ASND vs CASI

Header iconASND vs CASI Comparison
Open Charts ASND vs CASIBanner chart's image
Ascendis Pharma A/S
Price$173.10
Change+$1.10 (+0.64%)
Volume$270.61K
Capitalization10.47B
CASI Pharmaceuticals
Price$1.33
Change-$0.00 (-0.00%)
Volume$72.53K
Capitalization20.61M
ASND vs CASI Comparison Chart in %
Loading...
ASND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CASI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ASND vs. CASI commentary
Jul 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ASND is a Hold and CASI is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 03, 2025
Stock price -- (ASND: $173.10 vs. CASI: $1.33)
Brand notoriety: ASND and CASI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ASND: 58% vs. CASI: 53%
Market capitalization -- ASND: $10.47B vs. CASI: $20.61M
ASND [@Biotechnology] is valued at $10.47B. CASI’s [@Biotechnology] market capitalization is $20.61M. The market cap for tickers in the [@Biotechnology] industry ranges from $306.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ASND’s FA Score shows that 0 FA rating(s) are green whileCASI’s FA Score has 0 green FA rating(s).

  • ASND’s FA Score: 0 green, 5 red.
  • CASI’s FA Score: 0 green, 5 red.
According to our system of comparison, ASND is a better buy in the long-term than CASI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ASND’s TA Score shows that 2 TA indicator(s) are bullish while CASI’s TA Score has 5 bullish TA indicator(s).

  • ASND’s TA Score: 2 bullish, 5 bearish.
  • CASI’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, CASI is a better buy in the short-term than ASND.

Price Growth

ASND (@Biotechnology) experienced а +0.06% price change this week, while CASI (@Biotechnology) price change was +2.73% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.32%. For the same industry, the average monthly price growth was +33.16%, and the average quarterly price growth was +1.56%.

Reported Earning Dates

ASND is expected to report earnings on Sep 09, 2025.

CASI is expected to report earnings on May 16, 2025.

Industries' Descriptions

@Biotechnology (+1.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ASND($10.5B) has a higher market cap than CASI($20.6M). ASND YTD gains are higher at: 25.735 vs. CASI (-52.993). CASI has higher annual earnings (EBITDA): -38.42M vs. ASND (-287.37M). ASND has more cash in the bank: 518M vs. CASI (12.7M). CASI has less debt than ASND: CASI (18.5M) vs ASND (847M). ASND has higher revenues than CASI: ASND (369M) vs CASI (31.4M).
ASNDCASIASND / CASI
Capitalization10.5B20.6M50,971%
EBITDA-287.37M-38.42M748%
Gain YTD25.735-52.993-49%
P/E RatioN/AN/A-
Revenue369M31.4M1,175%
Total Cash518M12.7M4,079%
Total Debt847M18.5M4,578%
FUNDAMENTALS RATINGS
ASND vs CASI: Fundamental Ratings
ASND
CASI
OUTLOOK RATING
1..100
6087
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
73
Overvalued
PROFIT vs RISK RATING
1..100
74100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4495
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CASI's Valuation (73) in the Biotechnology industry is in the same range as ASND (90). This means that CASI’s stock grew similarly to ASND’s over the last 12 months.

ASND's Profit vs Risk Rating (74) in the Biotechnology industry is in the same range as CASI (100). This means that ASND’s stock grew similarly to CASI’s over the last 12 months.

ASND's SMR Rating (100) in the Biotechnology industry is in the same range as CASI (100). This means that ASND’s stock grew similarly to CASI’s over the last 12 months.

ASND's Price Growth Rating (44) in the Biotechnology industry is somewhat better than the same rating for CASI (95). This means that ASND’s stock grew somewhat faster than CASI’s over the last 12 months.

ASND's P/E Growth Rating (100) in the Biotechnology industry is in the same range as CASI (100). This means that ASND’s stock grew similarly to CASI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ASNDCASI
RSI
ODDS (%)
Bearish Trend 1 day ago
71%
Bullish Trend 1 day ago
80%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
73%
Bullish Trend 1 day ago
83%
Momentum
ODDS (%)
Bullish Trend 1 day ago
73%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
72%
Bearish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
69%
Bullish Trend 1 day ago
78%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
73%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
N/A
Bullish Trend 1 day ago
82%
Declines
ODDS (%)
Bearish Trend 6 days ago
77%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
76%
Bullish Trend 1 day ago
74%
Aroon
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
ASND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CASI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GFAFX81.180.51
+0.63%
American Funds Growth Fund of Amer F1
DNEMX15.64N/A
N/A
Dunham Emerging Markets Stock N
AEDRX35.93N/A
N/A
Invesco EQV European Equity R
MGRPX65.37N/A
N/A
Morgan Stanley Inst Growth R6
CVMAX20.00N/A
N/A
Calvert Emerging Markets Equity A

ASND and

Correlation & Price change

A.I.dvisor indicates that over the last year, ASND has been loosely correlated with NUVL. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ASND jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ASND
1D Price
Change %
ASND100%
+0.64%
NUVL - ASND
39%
Loosely correlated
+3.19%
ORMP - ASND
37%
Loosely correlated
+2.86%
ZNTL - ASND
36%
Loosely correlated
+4.20%
AMRN - ASND
35%
Loosely correlated
-0.95%
AXON - ASND
34%
Loosely correlated
-0.09%
More

CASI and

Correlation & Price change

A.I.dvisor tells us that CASI and ASND have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CASI and ASND's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CASI
1D Price
Change %
CASI100%
+0.02%
ASND - CASI
33%
Poorly correlated
+0.64%
RIGL - CASI
29%
Poorly correlated
-0.48%
ADCT - CASI
29%
Poorly correlated
+4.87%
SRPT - CASI
28%
Poorly correlated
+2.74%
AURA - CASI
27%
Poorly correlated
+3.19%
More